Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (868)	6/7/2007 4:33:20 AM
From: nigel bates	Respond to of 1022

Thanks for posting that. ...Overall, there is much optimism regarding the future of alternative affinity reagents. But several problems have to be overcome before they are adopted more widely by the scientific community. One of the most pressing issues is the inability to produce these reagents at a truly high-throughput scale. Overcoming this obstacle would make these alternative binders not only cheaper to produce than traditional antibodies, but would also require significantly less time. "I would love to see a major technology breakthrough where someone shows that you can actually produce these in a high-throughput manner, but so far I don't think anyone has been able to do that," says Uhlén...